Covid-19: Zydus Cadila gets Emergency Use Approval of antiviral drug Virafin from DCGI | Editorji
  1. home
  2. > national
  3. > Will Virafin be a game changer Covid drug? Regulator gives emergency nod
prev iconnext button of playermute button of playermaximize icon
mute icontap to unmute
video play icon
00:00/00:00
prev iconplay paus iconnext iconmute iconmaximize icon
close_white icon

Will Virafin be a game changer Covid drug? Regulator gives emergency nod

Apr 23, 2021 17:43 IST | By Editorji News Desk

Zydus Cadila on Friday announced that it has received restricted emergency use approval from the Drug Controller General of India (DCGI) to use antiviral drug Virafin for the treatment of moderate COVID-19 infections. A single dose subcutaneous regimen of the antiviral drug will make treatment of COVID-19 disease more convenient.

In a multi-centric trial conducted in 20-25 centres across India, Zydus says 91.15% of patients treated with the drug showed negative RT-PCR results by day 7, adding that the treatment significantly reduces the hours of supplemental oxygen in the patients.

Zydus in its regulatory filing said, when administered early on during Covid, Virafin will help patients recover faster and avoid most of the complications. Virafin will be available only on prescription for now, for use in a hospital or institutional setup.

National